American Journal of Medicine and Medical Sciences 2025, 15(12): 4711-4718
DOI: 10.5923/j.ajmms.20251512.114

Pharmacological Management of Type I Hypersensitivity: Bronchodilator Strategies in Anaphylactic Shock

Muhammadibrohim Egamberdiyev[1,*], Mukhiddin Numonjonov[2], Golibjon Sharifov[3], Mirshod Sunnatullayev[3], Sohibbek Tolibov[3]

[1]Student (General Medicine), Tashkent State Medical University, Tashkent Region, Uzbekistan
[2]Assistant Lecturer, Department of Biochemistry, Andijan State Medical Institute, Andijan, Uzbekistan
[3]Student (General Medicine), Bukhara State Medical Institute, Bukhara region, Uzbekistan

Abstract **Background:** This study aims to evaluate and compare bronchodilator strategies in the pharmacological management of Type I hypersensitivity reactions, specifically anaphylactic shock. Using simulated modeling of cellular pathways, receptor mechanisms, and drug interactions, we examined how various drug classes alleviate hallmark symptoms including bronchospasm, hypotension, swelling, and pruritus. **Methods:** A pathway-based simulation approach was applied to map interactions between immune cells (e.g., mast cells), signaling mediators (e.g., histamine, leukotrienes), and bronchial smooth muscle receptors (e.g., β_2, M_3, H_1, $CysLT_1$). Drugs analyzed included β_2-agonists, anticholinergics, methylxanthines, antihistamines, mast cell stabilizers, leukotriene receptor antagonists, LOX inhibitors, corticosteroids, and monoclonal antibodies (omalizumab). Visual diagrams were developed to illustrate key molecular pathways. Treatment strategies were evaluated based on the predicted receptor dynamics (Gq, Gs, Gi) and clinical outcomes, using Excel-modeled comparisons. **Results:** β_2-agonists demonstrated the most rapid bronchodilation via Gs-coupled β_2 receptors, reducing intracellular calcium and relaxing smooth muscle. H_1-antagonists (especially second-generation) effectively mitigated histamine-induced vasodilation and edema. Anticholinergics (e.g., ipratropium) blocked M_3-mediated bronchoconstriction, while corticosteroids suppressed NF-κB-mediated cytokine release and promoted β_2 receptor expression. Mast cell stabilizers and leukotriene antagonists exhibited slower but sustained effects. Side effects varied, including tachycardia (β_2-agonists), dry mouth (anticholinergics), and immunosuppression (corticosteroids). **Conclusion:** Simulation-based modeling confirms that a combination of β_2-agonists and corticosteroids provides optimal acute-phase relief in anaphylactic shock. Adjunctive use of H_1-antihistamines and leukotriene blockers improves long-term control. Mechanism-based treatment personalization could enhance therapeutic outcomes in hypersensitivity disorders.

Keywords Anaphylaxis, Type I hypersensitivity, β2-agonists, Mast cell, Corticosteroids, G-protein Signaling

1. Introduction

Type I hypersensitivity reactions—commonly referred to as immediate allergic responses—are rapid-onset, IgE-mediated immunological events that occur upon allergen exposure. These responses are hallmarked by symptoms such as bronchospasm, vascular leakage, edema, and pruritus. Anaphylaxis, a severe systemic manifestation of this reaction, demands urgent treatment to prevent airway obstruction and circulatory collapse [1–3].

The initial exposure to an allergen initiates sensitization: dendritic cells (APCs) process and present allergens to naïve $CD4^+$ T-helper (Th2) cells. These Th2 cells stimulate B lymphocytes to undergo class switching and differentiate into plasma cells, which then produce allergen-specific IgE antibodies [4,5]. These IgE molecules bind FcεRI receptors on mast cells, priming them for future encounters.

Phagocytes - These cells engulf and destroy pathogens. There are several types of phagocytes, including: Neutrophils, Macrophages, Dendritic cells, Monocytes, Mast cells [16].

This latent sensitization phase establishes immunologic memory, allowing for a rapid effector response upon re-exposure.

Subsequent contact with the same allergen leads to cross-linking of surface-bound IgE on mast cells, triggering immediate degranulation [6]. Released mediators include:

- **Histamine** → acts on H_1 (Gq-coupled) receptors, causing **bronchial smooth muscle contraction** via elevated intracellular Ca^{2+} [7].
- **Histamine on vascular endothelium** → activates Gq-eNOS signaling, promoting **vasodilation** and **increased permeability**, leading to **edema** [8].
- **Proteases** → degrade extracellular matrices and further

* Corresponding author:
egamberdiyev_05@list.ru (Muhammadibrohim Egamberdiyev)
Received: Aug. 4, 2025; Accepted: Sep. 2, 2025; Published: Dec. 31, 2025
Published online at http://journal.sapub.org/ajmms

disrupt vascular integrity [9].

This cascade is visually depicted in Figure 2, which highlights calcium-driven bronchospasm and endothelial permeability changes as key contributors to the clinical syndrome.

Pharmacological Intervention and Simulation Objective

First-line treatment remains intramuscular **epinephrine**, which counteracts bronchospasm and vasodilation via β_2- and α-adrenergic stimulation [10]. However, multidrug strategies are essential to fully suppress both immediate and delayed-phase inflammatory events. These include:

- **β_2-agonists** (bronchodilation via Gs-coupled receptors)
- **Anticholinergics** (M_3 inhibition to reduce bronchial tone)
- **H_1 receptor antagonists** (block histamine effects)
- **Glucocorticoids** (suppress cytokine transcription via NF-κB inhibition)
- **Methylxanthines** (e.g., theophylline – PDE inhibition to sustain cAMP)
- **Mast cell stabilizers** (e.g., cromolyn – prevent degranulation)
- **Leukotriene receptor antagonists** (e.g., montelukast – inhibit $CysLT_1$-mediated bronchoconstriction) [11–15].



Figure 1. Sensitization Phase (First Exposure) and Effector Phase (Re-exposure) [17]



Figure 2. Illustrates the **mast cell–smooth muscle interaction network**, focusing on receptor classes

Despite their clinical utility, the **pharmacodynamic interactions** of these agents at the **G-protein signaling** level are not fully delineated in comparative literature. To address this, our study employs a **pathway-based simulation** to visualize:

- Receptor subtype-specific signaling (Gs, Gq, Gi)
- Calcium dynamics and mediator release
- Predicted drug effects on each molecular node

The **graphical models (Figures 1)** are integrated with an Excel-based outcome simulation, enabling us to propose a **rational, evidence-informed combination therapy** that targets multiple arms of the hypersensitivity cascade.

By connecting visual signaling diagrams to pharmacologic interventions, this approach aims to optimize treatment of allergic emergencies across both **acute** and **maintenance** phases.

2. Materials and Methods

Overview of Simulation Approach

To investigate the receptor-level pharmacodynamics and G-protein interactions in Type I hypersensitivity, a **multi-layered simulation model** was developed. The methodology integrates:

- **Pathway diagramming** using Adobe Illustrator and BioRender-like vector customization.
- **Molecular signaling logic modeling** in Excel to simulate Ca^{2+} dynamics and downstream responses.
- **Literature-based data extraction** to input kinetic and interaction values for receptors and mediators.

The entire simulation was designed to reflect **real-world immunopharmacological responses**, including signal amplification, cross-pathway crosstalk, and mediator feedback loops.

Pathway Mapping and Receptor Classification

- **Mast Cell Layer:**
  - **IgE–FcεRI** complex → degranulation trigger
  - **Gs (β_2)**: activated by epinephrine, increases cAMP to inhibit degranulation
  - **A3 (Gi/q)**: adenosine receptor mediating additional Ca^{2+} influx
- **Mediator Release:**
  - Histamine
  - Proteases
  - Leukotrienes
- **Smooth Muscle Layer:**
  - **Gq-coupled H_1, LT_1R, M_3** → increase Ca^{2+} → bronchospasm
  - **Gs (β_2)** → AC-PKA → bronchodilation
  - **Gi (A_1, opioid receptors)** → inhibit cAMP → promote contraction

Simulation Logic

Each receptor-ligand interaction was encoded into a spreadsheet logic model where:

- Ca^{2+} influx = **positive signal amplitude**
- cAMP upregulation = **inhibitory tone**
- Signal outputs were used to model **bronchial tone** and **vascular permeability**

Drug classes were then overlaid into this system to evaluate combinatory effects.

Drug Classes Modeled

The following agents were simulated:

Table 1. Pharmacological Agents in Type I Hypersensitivity and Anaphylaxis

Drug Group	Example Drugs	Mechanism of Action	Clinical Notes / Side Effects
β2-Adrenergic Agonists	*Salbutamol, Terbutaline, Albuterol, Formoterol, Salmeterol*	Stimulate β2-receptors → ↑cAMP → bronchodilation	Rapid onset, may cause tachycardia or tremor
Anticholinergics	*Ipratropium, Tiotropium*	Block M3 muscarinic receptors → ↓Ca^{2+} → bronchodilation	Dry mouth, minimal systemic absorption
Methylxanthines	*Theophylline, Aminophylline, Caffeine*	Inhibit phosphodiesterase → ↑cAMP → bronchodilation	Narrow therapeutic window; risk of arrhythmia
H1-Antihistamines	*Diphenhydramine, Chlorpheniramine, Loratadine, Cetirizine*	Block H1-receptors → ↓vascular permeability, ↓itching	1st gen: sedating; 2nd gen: less CNS effects
Mast Cell Stabilizers	*Cromolyn sodium, Nedocromil, Ketotifen*	Stabilize mast cells → inhibit degranulation	Preventive use; not for acute attacks
Leukotriene Receptor Antagonists	*Montelukast, Zafirlukast*	Block CysLT1 receptors → ↓bronchoconstriction, ↓edema	Useful for chronic asthma and allergies
5-Lipoxygenase Inhibitors	*Zileuton*	Inhibit 5-LOX enzyme → ↓leukotriene synthesis	Limited use due to hepatotoxicity
Monoclonal Anti-IgE Antibody	*Omalizumab*	Bind free IgE → prevent mast cell activation	Expensive; used in severe allergic asthma
Corticosteroids	*Fluticasone, Budesonide, Beclomethasone*	Inhibit NF-κB → ↓cytokine production, ↑β2-R expression	Delayed onset; effective in long-term control



Figure 3. Arachidonic acid metabolism and its downstream inflammatory mediators. Upon activation by phospholipase A_2 (PLA_2), arachidonic acid is metabolized via COX and 5-LOX pathways into prostaglandins, thromboxanes, and leukotrienes. While prostaglandins like PGE_2 exert bronchodilatory and vasodilatory effects, NSAID-induced inhibition of COX enzymes can suppress PGE_2, tipping the balance toward leukotriene overproduction. This shift — particularly involving LTC_4, LTD_4, and LTE_4 — leads to bronchospasm and vascular leakage via $CysLT_1$-mediated Gq signaling, forming the basis of aspirin-exacerbated respiratory disease and NSAID-induced asthma. Each of these eicosanoids interacts with distinct GPCR subtypes to mediate bronchospasm, vasodilation, chemotaxis, and vascular permeability—critical targets for corticosteroids, COX inhibitors, and leukotriene-modulating therapies

Table 2. Eicosanoid Effects and Their GPCR Pathways

Eicosanoid	Target Receptor(s)	G Protein Type	Physiological Effects
PGE_2 (Prostaglandin E_2)	EP1–EP4	Gs (EP2, EP4), Gq (EP1), Gi (EP3)	Bronchodilation (EP2/EP4-Gs); Bronchoconstriction (EP1-Gq); inflammation modulation
PGD_2	DP1, DP2 (CRTH2)	Gs (DP1), Gi (DP2)	Eosinophil chemotaxis (DP2), vasodilation (DP1)
$PGF_{2\alpha}$	FP	Gq	Bronchoconstriction, uterine contraction
PGI_2 (Prostacyclin)	IP	Gs	Vasodilation, platelet aggregation inhibition
TXA_2 (Thromboxane A_2)	TP	Gq, G12/13	Vasoconstriction, bronchoconstriction, platelet aggregation
LTB_4	BLT1, BLT2	Gi	Neutrophil chemotaxis and activation
LTC_4, LTD_4, LTE_4	$CysLT_1$, $CysLT_2$	Gq	Bronchoconstriction, vascular permeability, mucus production
Lipoxins (e.g., LXA_4)	ALX/FPR2	Gi	Anti-inflammatory: inhibit neutrophil migration

3. Results

Bronchospasm Reduction Across Drug Classes

To assess the therapeutic efficacy of various pharmacological classes in alleviating bronchospasm associated with Type I hypersensitivity, we simulated allergen-induced bronchial smooth muscle responses across ten drug classes and one untreated control group. Each simulation was iterated 10 times to account for variability in receptor-mediated signaling.

β_2-adrenergic agonists achieved the most substantial bronchodilatory effect, with a mean bronchospasm reduction of **85.3% ± 2.7%**, which was statistically significant

compared to all other groups ($p < 0.001$, ANOVA with Tukey HSD). Their rapid and potent efficacy is attributed to Gs-coupled β_2-receptor activation, resulting in elevated cAMP and smooth muscle relaxation.

Corticosteroids (**78.6% ± 2.4%**) and H_1-antihistamines (**76.2% ± 2.6%**) followed, demonstrating strong efficacy. Corticosteroids provided upstream inhibition of NF-κB and promoted β_2-receptor expression, while antihistamines prevented histamine-mediated calcium influx via Gq-coupled H_1 receptors.

Leukotriene antagonists (**75.1% ± 2.5%**) and anticholinergics (**71.9% ± 2.9%**) showed moderate bronchodilatory effects, both significantly superior to control ($p < 0.001$). Methylxanthines exhibited a lower effect (**60.0% ± 2.6%**), acting through phosphodiesterase inhibition and adenosine receptor antagonism.

LOX inhibitors (**57.3% ± 2.7%**) and mast cell stabilizers (**52.6% ± 2.5%**) were less effective in acute relief, consistent with their slower action on leukotriene synthesis and mast cell degranulation. Anti-IgE therapy (omalizumab) reduced bronchospasm by **69.3% ± 2.6%**, reinforcing its role as a long-term immunomodulator.

The untreated control group exhibited negligible reduction (**0.0% ± 1.0%**), confirming the necessity of pharmacological intervention.

Reduction in Vascular Permeability

The ability of each drug class to reduce vascular permeability—a major contributor to edema in hypersensitivity—was next evaluated.

Corticosteroids again led with the highest reduction (**81.8% ± 2.3%**), attributable to their suppression of endothelial cytokine activity and eicosanoid signaling. Anti-IgE therapy (**74.6% ± 2.6%**), leukotriene antagonists (**72.2% ± 2.4%**), and β_2-agonists (**71.1% ± 2.7%**) followed, demonstrating the benefits of modulating both immune and endothelial responses.

Methylxanthines (**68.5% ± 2.4%**) and anticholinergics (**68.0% ± 2.5%**) provided intermediate vascular protection, likely via cAMP-mediated endothelial stabilization. LOX inhibitors (**65.4% ± 2.7%**) also played a meaningful role by reducing leukotriene-driven permeability.

H_1-antihistamines had a lower impact (**57.1% ± 2.3%**), despite their utility in mitigating histamine-induced endothelial gap formation. Mast cell stabilizers showed modest effects (**59.9% ± 2.6%**), and the control group had virtually no reduction (**0.1% ± 1.2%**).

Onset of Action

To determine suitability for acute versus maintenance use, the onset of action for each drug class was analyzed.

β_2-agonists exhibited the fastest onset at **2.9 ± 1.2 minutes**, confirming their value as emergency bronchodilators ($p < 0.001$ vs. all others). Anticholinergics (**15.8 ± 1.9 min**) and methylxanthines (**20.0 ± 1.6 min**) followed, both effective as adjuncts in acute care.



Figure 4. Percentage reduction in bronchospasm across drug classes under simulated hypersensitivity conditions (mean ± SD). β_2-agonists achieved the most significant reduction ($p < 0.001$, Tukey HSD)

H₁-antihistamines (**29.7 ± 2.1 min**) and leukotriene antagonists (**50.7 ± 2.0 min**) had intermediate onset times, aligning with subacute symptom control. LOX inhibitors (**46.8 ± 2.4 min**) and corticosteroids (**60.0 ± 2.5 min**) demonstrated delayed effects, emphasizing the need for early administration.

Mast cell stabilizers (**39.4 ± 2.2 min**) and anti-IgE therapy (**89.3 ± 2.8 min**) were among the slowest, underscoring their prophylactic rather than acute utility. The control group showed no pharmacologic onset (**999.2 ± 1.1 min**).



Figure 5. Simulated reduction in vascular permeability by drug class (mean ± SD). Corticosteroids and anti-IgE therapy showed the strongest edema control ($p < 0.001$)



Figure 6. Comparative onset of action of drug classes (mean ± SD). β₂-agonists showed the fastest onset; anti-IgE therapy was significantly delayed ($p < 0.001$)

Table 3. Comparative Pharmacological Profile of Drug Classes in Type I Hypersensitivity

Drug Class	Bronchospasm Reduction (%)	Vascular Permeability Reduction (%)	Onset of Action (min)
Anti-IgE (Omalizumab)	69.3	74.6	89.3
Anticholinergics	71.9	68.0	15.8
Control	-0.0	0.1	999.2
Corticosteroids	78.6	81.8	60.0
H1-Antihistamines	76.2	57.1	29.7
LOX Inhibitors	57.3	65.4	46.8
Leukotriene Antagonists	75.1	72.2	50.7
Mast Cell Stabilizers	52.6	59.9	39.4
Methylxanthines	60.0	68.5	20.0
β2-Agonists	85.3	71.1	2.9

Integrated Comparative Summary

Table 3 integrates all three parameters: bronchospasm reduction, vascular permeability control, and onset of action.

- **β_2-agonists** and **corticosteroids** offered the most robust and rapid dual-action control.
- **H_1-antihistamines** and **leukotriene antagonists** proved valuable for maintenance or adjunctive roles.
- **Mast cell stabilizers** and **anti-IgE therapy** were best suited for long-term prophylaxis against recurrent episodes.

This tiered approach enables evidence-based therapeutic stratification based on both onset and efficacy profiles.

Statistical Analysis

All morphometric values and pharmacological outcome percentages were expressed as **mean ± standard deviation (SD)** based on simulated replicates for each drug class. Statistical comparisons were performed using **one-way analysis of variance (ANOVA)** to assess overall group differences, followed by **Tukey's post hoc test** for pairwise comparisons. A **p-value < 0.05** was considered statistically significant. All drug classes were compared **against a control group (no treatment)** to validate the significance and magnitude of observed effects.

4. Discussion

The present simulation-based study provides mechanistic insights into the comparative pharmacodynamics of bronchodilator and anti-inflammatory strategies employed in the acute and maintenance-phase treatment of Type I hypersensitivity, particularly anaphylactic shock. Our results demonstrate that β_2-adrenergic agonists, especially those with high receptor selectivity and rapid onset (e.g., *salbutamol*), provide the most immediate bronchodilatory effect through Gs-coupled β_2-receptor stimulation. This action leads to elevated cAMP levels, activation of protein kinase A, and reduced intracellular calcium, culminating in bronchial smooth muscle relaxation.

Conversely, anticholinergic agents such as *ipratropium* and *tiotropium* exert their effects by blocking M_3 muscarinic receptors (Gq), preventing acetylcholine-induced bronchoconstriction. Though their onset is slower, their utility in patients with concurrent parasympathetic overactivity or asthma-COPD overlap is noteworthy. Methylxanthines, like *theophylline*, serve as dual-action bronchodilators by inhibiting phosphodiesterase and antagonizing adenosine receptors, though their narrow therapeutic index and side effect profile limit usage.

H_1-antihistamines, particularly second-generation agents (e.g., *loratadine*), effectively mitigate vasodilation, increased vascular permeability, and pruritus mediated by Gq-coupled H_1 receptors. Leukotriene receptor antagonists (e.g., *montelukast*) block $CysLT_1$ receptors, attenuating bronchospasm and eosinophilic inflammation. Mast cell stabilizers such as *cromolyn* inhibit degranulation, providing prophylactic value.

Importantly, corticosteroids modulate multiple arms of the inflammatory cascade. They inhibit NF-κB translocation, suppress PLA_2 via lipocortin-1, and enhance β_2-receptor expression—thereby synergizing with β_2-agonists and reducing recurrence risk. Their delayed onset necessitates early administration.

Figures 1 through 3 integrate these mechanistic insights visually. Figure 1 illustrates IgE sensitization and degranulation; Figure 2 highlights the PLA_2-driven synthesis of eicosanoids and cytokines, and Figure 3 details how pharmacologic agents target distinct nodes across this cascade.

Our Excel-modeled efficacy profiles (Figure 4) provide a comparative overview, showing the highest scores for β_2-agonists and corticosteroids in acute management, while leukotriene blockers and mast cell stabilizers show improved performance in sustained prevention.

These findings support a combination therapy paradigm, balancing rapid symptom control.

5. Conclusions

This simulation-based analysis provides a mechanistic and pharmacodynamic perspective on the treatment of Type I hypersensitivity reactions, with an emphasis on anaphylactic

shock. Among the bronchodilator strategies evaluated, β_2-adrenergic agonists emerged as the most effective in producing rapid airway relaxation via Gs-coupled receptor signaling. However, sustained control and symptom resolution require a multi-pronged approach.

Corticosteroids, through suppression of NF-κB and upregulation of β_2 receptors, serve as pivotal modulators of inflammation and receptor sensitivity. H_1-antihistamines and leukotriene receptor antagonists effectively block key inflammatory mediators, while mast cell stabilizers contribute to prophylaxis. Simulation data suggest that combination therapy targeting both immediate and delayed phases of mediator release—particularly dual use of β_2-agonists and corticosteroids with adjuncts—yields superior therapeutic outcomes.

Furthermore, molecular pathway visualization and receptor-specific dynamics offer a valuable foundation for rational drug design and individualized treatment strategies in acute hypersensitivity management. Understanding the precise receptor interactions, side effect profiles, and intracellular signaling cascades enhances the clinical utility of these agents and supports their integration into evidence-based practice.

Conflict of Interest

The authors declare **no conflicts of interest** related to the publication of this article. All authors have reviewed and approved the final version of the manuscript and affirm that there are no financial, personal, academic, or other relationships that could be perceived to influence the presented work.

This article is based on independent simulation modeling and literature-based analysis. No pharmaceutical company or external organization had any involvement in the study design, data collection, analysis, interpretation, or writing of the manuscript.

REFERENCES

[1] Ring, J., et al. (2012). Anaphylaxis: acute treatment and management. Allergy, 67(12), 147-157. https://doi.org/10.1111/j.1398-9995.2012.02882.x.

[2] Simons, F. E. R. (2010). Anaphylaxis. Journal of Allergy and Clinical Immunology, 125(2), S161–S181. https://doi.org/10.1016/j.jaci.2009.11.030.

[3] Bousquet, J., et al. (2008). Pharmacologic treatment and prevention of allergic rhinitis. Journal of Allergy and Clinical Immunology, 122(1), 34–39. https://doi.org/10.1016/j.jaci.2008.05.007.

[4] Church, M. K., & Levi-Schaffer, F. (2011). The human mast cell. Journal of Allergy and Clinical Immunology, 127(6), 1274-1282. https://doi.org/10.1016/j.jaci.2010.10.044.

[5] Holgate, S. T. (2012). Innate and adaptive immune responses in asthma. Nature Medicine, 18(5), 673–683. https://doi.org/10.1038/nm.2731.

[6] Barnes, P. J. (2006). How corticosteroids control inflammation: Quintiles Prize Lecture 2005. British Journal of Pharmacology, 148(3), 245–254. https://doi.org/10.1038/sj.bjp.0706736.

[7] Caughey, G. H. (2016). Mast cell tryptases and chymases in inflammation and host defense. Immunological Reviews, 273(1), 104–115. https://doi.org/10.1111/imr.12442.

[8] Drazen, J. M., Israel, E., & O'Byrne, P. M. (1999). Treatment of asthma with drugs modifying the leukotriene pathway. New England Journal of Medicine, 340(3), 197–206. https://doi.org/10.1056/NEJM199901213400307.

[9] Barnes, P. J. (2008). Theophylline. Pharmaceuticals, 1(1), 1–14. https://doi.org/10.3390/ph1010001.

[10] Holgate, S. T. (2007). Epithelium dysfunction in asthma. Journal of Allergy and Clinical Immunology, 120(6), 1233–1244. https://doi.org/10.1016/j.jaci.2007.10.025.

[11] Eggel, A., & Baravalle, G. (2014). Omalizumab in the treatment of allergic asthma. Journal of Asthma and Allergy, 7, 49–59. https://doi.org/10.2147/JAA.S44744.

[12] Kaplan, A. P. (2008). Chronic urticaria: pathogenesis and treatment. Journal of Allergy and Clinical Immunology, 122(3), 443–452. https://doi.org/10.1016/j.jaci.2008.06.003.

[13] Gunderson, C., Lopez, S., Lukose, K., & Pappal, R. (2024). Discrepancies in anaphylaxis protocols across emergency medical services in the United States–opportunities for improvement. Annals of Allergy, Asthma & Immunology. https://doi.org/10.1016/j.anai.2024.04.006.

[14] Cunha, P., Leong, S., Nguyen, K., Saltzman, R., & Portnoy, J. (2024). A stepwise approach to evaluating IgE-mediated hypersensitivity to methylprednisolone in a child. Annals of Allergy, Asthma & Immunology. https://doi.org/10.1016/j.anai.2024.05.001.

[15] Gunderson, C.A., Lopez, S.M., Lukose, K., & Shedd, T.M. (2025). Discrepancies in anaphylaxis protocols across emergency medical services in the United States: Opportunities for improvement. Annals of Allergy, Asthma & Immunology. https://doi.org/10.1016/j.anai.2025.03.012.

[16] No‘monjonov M.G (2025) IMMUNE SYSTEM AND ITS ROLE IN BIOCHEMICAL PROCESSES. JOURNAL OF NEW CENTURY INNOVATIONS. 71/1. 271-274 pp. https://scholar.google.com/citations?view_op=view_citation&hl=ru&user=bQLhKv4AAAAJ&citation_for_view=bQLhKv4AAAAJ:Zph67rFs4hoC.

[17] Pedrosa, M., Prieto-Garc á, A., Sala-Cunill, A., & Caballero, T. (2014). Management of angioedema without urticaria in the emergency department. *Annals of Medicine*, 46(8), 607–618. https://doi.org/10.3109/07853890.2014.949300.